Ibaflin
ibafloxacin
Table of contents
Withdrawn
This medicine is now withdrawn from use in the European Union.
Overview
The marketing authorisation for Ibaflin has been withdrawn at the request of the marketing authorisation holder.
This EPAR was last updated on 10/07/2013
Authorisation details
| Product details | |
|---|---|
| Name |
Ibaflin
|
| Agency product number |
EMEA/V/C/000052
|
| Active substance |
ibafloxacin
|
| International non-proprietary name (INN) or common name |
ibafloxacin
|
| Species |
|
| Anatomical therapeutic chemical veterinary (ATCvet) codes |
QJ01MA96
|
| Publication details | |
|---|---|
| Marketing-authorisation holder |
Intervet International BV
|
| Revision |
7
|
| Date of issue of marketing authorisation valid throughout the European Union |
13/06/2000
|
| Contact address |
Intervet International B.V.
Wim de Körverstraat 35 5831 AN Boxmeer The Netherlands |
Product information
26/05/2010 Ibaflin - EMEA/V/C/000052 - R/0019
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Pharmacotherapeutic group
Antibacterials for systemic use
Therapeutic indication
Therapeutic indication
Dogs:
Ibaflin is indicated for the treatment of the following conditions in dogs:
- dermal infections (pyoderma - superficial and deep, wounds, abscesses) caused by susceptible strains of Staphylococci, Escherichia coli and Proteus mirabilis;
- acute, uncomplicated urinary-tract infections, caused by susceptible strains of Staphylococci, Proteus species, Enterobacter spp., E. coli and Klebsiella spp.;
- respiratory-tract infections (upper tract) caused by susceptible strains of Staphylococci, E. coli, and Klebsiella spp.
Ibaflin gel is indicated in dogs for the treatment of the following conditions:
- dermal infections (pyoderma - superficial and deep, wounds, abscesses) caused by susceptible pathogens such as Staphylococcus spp., E. coli and P. mirabilis.
Cats:
Ibaflin gel is indicated in cats for treatment of the following conditions:
- dermal infections (soft-tissue infections - wounds, abscesses) caused by susceptible pathogens such as Staphylococcus spp., E. coli, Proteus spp. and Pasteurella spp.;
- upper respiratory-tract infections caused by susceptible pathogens such as Staphylococcus spp., E. coli, Klebsiella spp. and Pasteurella spp.